menu
    • menu

    Company profile for Goldfinch Bio, Inc

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates in the right patient subsets. This is achieved by applying a precision medicine approach to selecting patients most suitable for a given therapy. Goldfinch’s Kidne...
    Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates in the right patient subsets. This is achieved by applying a precision medicine approach to selecting patients most suitable for a given therapy. Goldfinch’s Kidney Genome AtlasTM represents the most comprehensive patient registry to investigate the underlying mechanisms of kidney disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Goldfinch Bio, IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    215 First Street, 4th Floor Cambridge, MA 02142
    Telephone
    Telephone
    +1-617-337-4200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.goldfinchbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/goldfinch-bio/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/goldfinchbio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Karuna plunders Goldfinch's nest to pad neuroscience pipeline
    Karuna plunders Goldfinch's nest to pad neuroscience pipeline

    03 Feb 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/karuna-plunders-goldfinchs-nest-pad-out-its-own-neuroscience-pipeline

    James Waldron FIERCE BIOTECH
    03 Feb 2023
    Share Share
    Goldfinch Bio has its wings clipped, shutting down after 7 years
    Goldfinch Bio has its wings clipped, shutting down after 7 years

    27 Jan 2023

    // Max Bayer FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/goldfinch-bio-falls-sky-after-failing-find-path-forward-kidney-treatments

    Max Bayer FIERCE BIOTECH
    27 Jan 2023
    Share Share
    Goldfinch Bio's Publication in Science Advances on Human Derived Organoids
    Goldfinch Bio's Publication in Science Advances on Human Derived Organoids

    07 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220707005157/en

    BUSINESSWIRE
    07 Jul 2022
    Share Share
    Goldfinch Bio to Present Initial Data from PI Trial of GFB-024 at ADA & ENDO
    Goldfinch Bio to Present Initial Data from PI Trial of GFB-024 at ADA & ENDO

    31 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220531005317/en

    BUSINESSWIRE
    31 May 2022
    Share Share
    Goldfinch Bio to Host Virtual Event on Unmet Need in FSGS and GFB-887
    Goldfinch Bio to Host Virtual Event on Unmet Need in FSGS and GFB-887

    22 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220322005400/en

    BUSINESSWIRE
    22 Mar 2022
    Share Share
    Goldfinch's kidney drug one-one in early phase 2 data
    Goldfinch's kidney drug one-one in early phase 2 data

    01 Mar 2022

    // Max Bayer FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/goldfinch-bios-early-phase-2-data-kidney-therapy-shows-clinical-benefit-not-across-board

    Max Bayer FIERCEBIOTECH
    01 Mar 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search